HPTN Bibliography

Balakrishnan P, Solomon S, Mohanakrishnan J, Cecelia AJ, Kumarasamy N, Murugavel KG, Venkatakrishnan B, Solomon SS, Crowe SM, Ganesh AK, Thyagarajan SP, Flanigan T, Mayer KH. A reliable and inexpensive EasyCD4 assay for monitoring HIV-infected individuals in resource-limited settings . J Acquir Immune Defic Syndr. 2006, 43: 23-6.

Batra M, Tien PC, Shafer RW, Contag CH, Katzenstein DA. HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe . AIDS Res Hum Retroviruses. 2000, 16: 973-9.

Becker-Pergola G, Mellquist JL, Guay L, Mmiro F, Ndugwa C, Kataaha P, Jackson JB, Eshleman SH. Identification of diverse HIV type 1 subtypes and dual HIV type 1 infection in pregnant Ugandan women . AIDS Res Hum Retroviruses. 2000, 16: 1099-04.

Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, Stablein D, Self S, McNamara J, Frey S, Flores J, Excler JL, Klein M, Habib RE, Duliege AM, Harro C, Corey L, Keefer M, M. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers . J Infect Dis. 2001, 183: 1343-52.

Bentley ME, Fullem AM, Tolley EE, Kelly CW, Jogelkar N, Srirak N, Mwafulirwa L, Khumalo-Sakutukwa G, Celentano DD. Acceptabilty of a microbicide among women and their partners in a 4-country phase 1 trial . Am J Public Health. 2004, 94: 1159-64.

Bentley ME, Morrow KM, Fullem A, Chesney MA, Horton SD, Rosenberg Z, Mayer KH. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women . Fam Plann Perspect. 2000, 32: 184-8.

Bentley ME, Spratt K, Shepherd ME, Gangakhedkar RR, Thilikavathi S, Bollinger RC, Mehendale SM. HIV testing and counseling among men attending STD clinics in Pune, India: Changes in condom use and sexual behavior over time . AIDS. 1998, 12: 1869-1877.

Brahmi A, Reid C, Mass B, Kelly C. Meeting Retention Challenges in Lusaka Zambia . Research Practitioner. 2006, 7: 212-13.

Brown EL, Wald A, Hughes JP, Morrow RA, Krantz E, Mayer K, Buchbinder S, Koblin B, Celum C. High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study . Am J Epidemiol. 2006, 164: 733-41.

Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of Enrollment in a Preventive HIV Vaccine Trial: Hypothetical Versus Actual Willingness and Barriers to Participation . J Acquir Immune Defic Syndr. 2004, 36: 604-12.

Cao H, Kaleebu P, Hom D, Flores J, Agrawal D, Jones N, Serwanga J, Okello M, Walker C, Sheppard H, El-Habib R, Klein M, Kebba A, Salata R, Mbidde E, Mugyenyi P, Walker B, Ellner J, Mugerwa R, and the HIV Network for Prevention Trials. Immunogenicity of a Recombinant Human Immunodeficiency Virus (HIV)-Canarypox Vaccine in HIV-Seronegative Ugandan Volunteers: Results of the HIV Network for Prevention Trials 007 Vaccine Study . J Infect Dis. 2003, 87: 887-95.

Carballo-Diéguez A, Balán IC, Morrow K, Rosen R, Mantell JE, Gai F, Hoffman S, Maslankowski L, El-Sadr W, Mayer K. Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050) . AIDS Care. 2007, 19: 1026-31.

Casper C, Carrell D, Miller KG, Judson FD, Meier AS, Pauk JS, Morrow RA, Corey L, Wald A, Celum C. HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study . Sex Transm Infect. 2006, 82: 229-35.

Casper C, Wald A, Pauk J, Tabet SR, Corey L, Celum CL. Correlates of prevalent and incident kaposi's sarcoma-associated herpesvirus infection in men who have sex with men . J Infect Dis. 2002, 185: 990-3.

Cates W Jr, Allen M. Mother-to-child HIV-1 transmission . Lancet. 2000, 356: 945.

Cavacini LA, Peterson JE, Nappi E, Duval M, Goldstein R, Mayer K, Posner MR. Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals . J Virol. 1999, 73: 9638-41.

Celentano DD. Editorial Response: It's All in the Measurement: Consistent Condom Use Is Effective in Preventing Sexually Transmitted Infections . Sex Transm Dis. 2004, 31: 161-62.

Celentano DD, Bond KC, Lyles CM, Eiumtrakul S, Go VF, Beyrer C, na Chiangmai C, Nelson KE, Khamboonruang C, Vaddhanaphuti C. Preventive intervention to reduce sexually transmitted infections: a field trial in the Royal Thai Army . Arch Intern Med. 2000, 160: 535-40.

Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Casapia, M, Ortiz A, Fuchs J, Buchbinder S, Koblin B, Zwerski S, Rose S, Wang J, Corey L, HPTN 039 Protocol Team. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a andomised, double-blind, placebo-controlled trial . Lancet. 2008, 371: 2109-19.

Celum CL, Buchbinder SP, Donnell D, Douglas JM Jr, Mayer K, Koblin B, Marmor M, Bozeman S, Grant RM, Flores J, Sheppard HW. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load . J Infect Dis. 2001, 183: 23-35.

Chasela C, Chen YQ, Fiscus S, Hoffman I, Young A, Valentine M, Emel L, Taha TE, Goldenberg RL, Read JS. Risk Factors for Late Postnatal Transmission of Human Immunodeficiency Virus Type 1 in Sub-Saharan Africa . Pediatr Infect Dis J. 2008, 27: 251-6.

Cherpes TL, Meyn LA, Krohn MA, Hillier SL. Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora . Sex Transm Dis. 2003, 30: 405-10.

Chesney MA, Koblin BA, Barresi PJ, Husnik MJ, Celum CL, Colfax G, Mayer K, McKirnan D, Judson FN, Huang Y, Coates TJ. An Individually Tailored Intervention for HIV Prevention: Baseline Data From the EXPLORE Study . Am J Public Health. 2003, 93: 933-8.

Chi BH, Wang L, Read JS, Sheriff M, Fiscus S, Brown ER, Taha TE, Valentine M, Goldenberg R. Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024 . AIDS. 2005, 19: 1857-64.

Chi BH, Wang L, Read JS, Taha TE, Sinkala M, Brown ER, Valentine M, Martinson F, Goldenberg RL. Predictors of stillbirth in sub-saharan Africa . Obstet Gynecol. 2007, 110: 989-97.

Chilongozi D, Wang L, Brown L, Taha T, Valentine M, Emel L, Sinkala M, Kafulafula G, Noor RA, Read JS, Brown ER, Goldenberg RL, Hoffman I; HIVNET 024 Study Team. Morbidity and mortality among a cohort of human immunodeficiency virus type 1-infected and uninfected pregnant women and their infants from Malawi, Zambia, and Tanzania . Pediatr Infect Dis J. 2008, 27: 808-14.

Chin-Hong PV, Vittinghoff E, Cranston RD, Browne L, Buchbinder S, Colfax G, Da Costa M, Darragh T, Benet DJ, Judson F, Koblin B, Mayer KH, Palefsky JM. Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study . J Natl Cancer Inst. 2005, 97: 896-05.

Chin-Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G, Da Costa M, Darragh T, Hess E, Judson F, Koblin B, Madison M, Palefsky JM. Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study . J Infect Dis. 2004, 190: 2070-6.

Church JD, Hudelson SE, Guay LA, Chen S, Hoover DR, Parkin N, Fiscus SA, Mmiro F, Musoke P, Kumwenda N, Jackson JB, Taha TE, Eshleman SH. HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D . AIDS Res Hum Retroviruses. 2007, 23: 764-68.

Church JD, Jones D, Flys T, Hoover D, Marlowe N, Chen S, Shi C, Eshleman JR, Guay LA, Jackson JB, Kumwenda N, Taha TE, Eshleman SH. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D . J Mol Diagn. 2006, 8: 430-2.

Clarke J, Peipert JF, Hillier SH, Heber W, Boardman L, Moench TR, Mayer K. Microflora changes with the use of a vaginal microbicide . Sex Transm Dis. 2002, 29: 288-93.

Coates TJ, Richter L, Caceres C.. Behavioural strategies to reduce HIV transmission: how to make them work better . Lancet. 2008, 372: 669-84.

Coletti A, Heagerty P, Sheon A, Gross M, Koblin B, Metzger D, Seage G. Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine trials . J Acquir Immune Defic Syndr. 2003, 32: 161-9.

Colfax G, Coates TJ, Husnik MJ, Huang Y, Buchbinder S, Koblin B, Chesney M, Vittinghoff E. Longitudinal patterns of methamphetamine, popper (Amyl Nitrite), and the cocaine use and high-risk sexual behavior among a cohort of San Francisco men who have sex with men . J Urban Health. 2005, 82: i62-i70.

Colfax G, Vittinghoff E, Husnik MJ, McKirnan D, Buchbinder S, Koblin B, Celum C, Chesney M, Huang Y, Mayer K, Bozeman S, Judson FN, Bryant KJ, Coates TJ, EXPLORE study team. Substance Use and Sexual Risk: A Participant- and Episode-level Analysis among a Cohort of Men Who Have Sex with Men . Am J Epidemiol. 2004, 159: 1002-12.

Collis TK, Celum CL. The clinical manifestations and treatment of sexually transmitted diseases in human immunodeficiency virus-positive men . Clin Infect Dis. 2001, 32: 611-22.

Cunningham S, Ank B, Lewis D, Wei L, Wantman W, Dileanis J, Jackson JB, Palumbo P, Krogstad P, and Eshleman SH. Performance of the Applied Biosystems ViroSeq HIV-1 Genotyping System for analysis of HIV-1 in pediatric plasma samples . J Clin Microbiology. 2001, 39: 1254-7.

Daley T. Impact of traditional healers on clinical research in Tanzania . Research Practitioner. 2006, 7: 216.

DeMaria, Jr,A, Kunches L, Mayer K, Cohen C, Epstein P, Werner B, Day J, DeCristofaro J, Landers S, Tang Y, Coady W, and the Massachusetts gp160 Working Group. Immune Responses to a Recombinant Human Immunodeficiency Virus Type 1 (HIV-1) gp160 Vaccine Among Adults with Advanced HIV Infection . J Hum Virol. 2000, 3: 182-92.

Des Jarlais DC, Marmor M, Friedmann P, Titus S, Aviles E, Deren S, Torian L, Glebatis D, Murrill C, Monterroso E, Friedman SR. HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic . Am J Public Health. 2000, 90: 352-9.

Dhawan D, Mayer KH.. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection . J Infect Dis. 2006, 193: 36-44.

El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, Mauck C, Absalon J, Morrow K, Masse B, Soto-Torres L, Kwiecien A and the HPTN 049 Team. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women . AIDS. 2006, 20: 1109-16.

Eshleman SH, Becker-Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, Cunningham S, Musoke P, Mmiro F, Jackson JB. Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study) . J Infect Dis. 2001, 184: 914-7.

Eshleman SH, Church JD, Chen S, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Kumwenda N, Jackson JB, Taha TE, Hoover DR. Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D . J Acquir Immune Defic Syndr. 2006, 42: 518-21.

Eshleman SH, Crutcher G, Petrauskene O, Kunstman K, Cunningham SP, Trevino C, Davis C, Kennedy J, Fairman J, Foley B, Kop J.. Sensitivity and specificity of the ViroSeq® HIV-1 Genotyping System for detection of HIV-1 drug resistance mutations using an ABI PRISM® 3100 Genetic Analyzer . J Clin Micro. 2005, 43: 813-17.

Eshleman SH, Gonzales MJ, Becker-Pergola G, Cunningham SC, Guay LA, Jackson JB, Shafer RW. Identification of Ugandan HIV Type 1 Variants with Unique Patterns of Recombination in pol Involving Subtypes A and D . AIDS Res Hum Retroviruses. 2002, 18: 507-11.

Eshleman SH, Guay LA, Fleming T, Mwatha A, Mracna M, Becker-Pergola G, Musoke, Mmiro F, Jackson JB. Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012) . J Acquir Immune Defic Syndr. 2002, 31: 327-30.

Eshleman SH, Guay LA, Mwatha A, Brown E, Musoke P, Mmiro F, Jackson JB. Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012 . J Acquir Immune Defic Syndr. 2005, 39: 593-97.

Eshleman SH, Guay LA, Mwatha A, Brown ER, Cunningham SP, Musoke P, Mmiro F, Jackson JB. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). . J Acquir Immune Defic Syndr. 2004, 35: 126-30.

Eshleman SH, Guay LA, Mwatha A, Cunningham SP, Brown ER, Musoke P, Mmiro F, Jackson JB. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012 . AIDS Res Hum Retroviruses. 2004, 20: 595-99.

Eshleman SH, Guay LA, Wang J, Mwatha A, Brown ER, Musoke P, Mmiro F, Jackson JB. Distinct Patterns of Emergence and Fading of K103N and Y181C in Women With Subtype A vs. D After Single-Dose Nevirapine: HIVNET 012 . J Acquir Immune Defic Syndr. 2005, 40: 24-9.

Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB, Kumwenda N, Taha T. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP . J Infect Dis. 2005, 192: 30-6.

Eshleman SH, Hoover DR, Chen SH, Hudelson SH, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB, Kumwenda N, and Taha T. Resistance after single dose nevirapine prophylaxis emerges in a high portion of Malawian newborns . AIDS. 2005, 19: 2167-68.

Eshleman SH, Hoover DR, Hudelson SE, Chen S, Fiscus SA, Piwowar-Manning E, Jackson JB, Kumwenda NI, Taha T. Development of nevirapine resistance is reduced by using infant-only nevirapine plus zidovudine post-exposure prophylaxis to prevent HIV-1 mother–to-child transmission . J Infect Dis. 2006, 193: 479-81.

Eshleman SH, Hudelson S, Gupta A, Bollinger R, Divekar AD, Gangakhedkar RR, Kulkarni SS, Thakar MR, Paranjape RS, and Tripathy S. Limited evolution in the HIV-1 pol region among acute seroconverters in Pune, India . AIDS Res Hum Retroviruses. 2005, 21: 93-97.

Eshleman SH, Hudelson SE, Bruce R, Lee T, Owens MR, Hackett J, Swanson P, Devare SG, and Marlowe N. Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strains . AIDS Res Hum Retroviruses. 2007, 23: 1593-8.

Eshleman SH, Husnik M, Hudelson S, Donnell D, Huang Y, Huang W, Hart S, Jackson JB, Coates T, Chesney M, and Koblin B. Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection . AIDS. 2007, 21: 1165-74.

Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis . AIDS Reviews. 2002, 4: 59-63.

Eshleman SH, Jones D, Flys T, Petrauskene O, and Jackson JB. Analysis of HIV-1 variants by cloning DNA generated with the ViroSeq HIV-1 Genotyping System . Biotechniques. 2003, 35: 614-8, 620, 622.

Eshleman SH, Jones D, Galovich J, Paxinos EE, Petropoulos CJ, Jackson JB, Parkin N. Phenotypic Drug Resistance Patterns in Subtype A HIV-1 Clones with Nonnucleoside Reverse Transcriptase Resistance Mutations . AIDS Res Hum Retroviruses. 2006, 22: 289-93.

Eshleman SH, Lie Y, Hoover DR, Chen S, Hudelson SE, Fiscus SA, Petropoulos CJ, Kumwenda N, Parkin N, and Taha TE. Association between the replication capacity and mother-to-child transmission of HIV-1, in antiretroviral drug-naïve Malawian women . J Infect Dis. 2006, 193: 1512-5.

Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, Jackson JB. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) . AIDS. 2001, 15: 1951-7.

Eshleman SH, Wang J, Guay LA, Cunningham SP, Mwatha A, Brown ER, Musoke P, Mmiro F, Jackson JB. Distinct patterns of selection and fading of K103N and Y181C are seen in women with subtype A vs. D HIV-1 after single dose nevirapine: HIVNET 012 . Antiviral Therapy. 2004, 9: S59.

Ferreira FGF. Daily challenges in study coordination, Brazil . Research Practitioner. 2006, 7: 221-22.

Fleming TR. Evaluating safety of interventions for prevention of perinatal transmission of HIV . Ann NY Acad Sci. 2000, 918: 201-211.

Fleming TR, Richardson BA. Some design issues in trials of microbicides for the prevention of HIV infection . J Infect Dis. 2004, 190: 666-74.

Flys T, Marlowe N, Hackett J, Parkin N, Schumaker M, Holzmayer V, Hay P, and Eshleman SH. Analysis of PTAP duplications in the gag p6 region of subtype C HIV-1 . AIDS Res Hum Retroviruses. 2005, 21: 739-41.

Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB, Eshleman JR, Eshleman SH. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012 . J Infect Dis. 2005, 192: 24-9.

Flys TS, Chen S, Jones DC, Hoover DR, Church JD, Fiscus SA, Mwatha A, Guay LA, Mmiro F, Musoke P, Kumwenda N, Taha TE, Jackson JB, Eshleman SH. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D . J Acquir Immune Defic Syndr. 2006, 42: 610-13.

Flys TS, Donnell D, Mwatha A, Nakabiito C, Musoke P, Mmiro F, Jackson JB, Guay LA, Eshleman SH. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission . J Infect Dis. 2007, 195: 711-5.

Flys TS, McConnell MS, Matovu F, Church JD, Bagenda D, Khaki L, Bakaki P, Thigpen MC, Eure C, Fowler MG, Eshleman SH. Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission . J Infect Dis. 2008, 198: 465-9.

Flys TS, Mwatha A, Guay LA, Nakabiito C, Donnell D, Musoke P, Mmiro F, Jackson JB, and Eshleman SH. Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine . AIDS. 2007, 21: 2077-82.

Gadkari DA, Quinn TC, Mehendale SM, Gangakhedkar RR, Divekar AD, Risbud AR, Chan-Tack K, Shepherd M, Gaydos C, Bollinger RC. HIV-1 DNA Shedding in Genital Ulcers and its Asscociated Risk Factors in Pune, India . J Acquir Immune Defic Syndr Hum Retrovirol. 1998, 18: 277-281.

Ganzura L, Latif A, Bassett M, Machekano R, Katzenstein DA, Mason PR. Syphilis serology and HIV infection in Harare, Zimbabwe . Sex Transm Infect. 1999, 75: 426-30.

Gaydos CA, Crotchfelt KA, Shah N, Tennant M, Quinn TC, Gaydos JC, McKee KT, Rompalo AM. Evaluation of dry vs. wet transported intravaginal swabs to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections by PCR in female soldiers . J Clin Microbiol. 2002, 40: 758-61.

Gaydos, C.A., Quinn TC, Willis D, Weissfeld A, Hook EW, Martin DH, Ferrero, Schachter J. Performance of the APTIMA Combo 2 assay for the multiplex detection of Chlamydia trachomatis and Neisseria gonorrheae in female urine and endocervical swab specimens . J Clin Microbiol. 2003, 41: 304-9.

Geise RE, Maenza J, Celum CL. Clinical challenges and diagnostic approaches to recognizing acute human immunodeficiency virus infection . Am J Med. 2001, 111: 237-8.

Genberg BL, Kawichai S, Chingono A, Sendah M, Chariyalertsak S, Konda KA, Celentano DD. Assessing HIV/AIDS Stigma and Discrimination in Developing Countries . AIDS Behav. 2007, E pub, ahead of print: .

Godbole S, Ghate M. Issues in managing and coordinating clinical research in India . Research Practitioner. 2006, 7: 219-20.

Goldenberg RL, Andrews WW, Hoffman I, Fawzi W, Valentine M, Young A, Read JS, Brown ER, Mudenda V, Kafulafula G, Mwinga K, Taha TE. Fetal Fibronectin and Adverse Pregnancy Outcomes in a Predominantly HIV-infected African Population . Obstet Gynecol. 2007, 109: 392-401.

Goldenberg RL, Mudenda V, Read JS, Brown ER, Sinkala M, Kamiza S, Martinson F, Kaaya E, Hoffman I, Fawzi W, Valentine M, Taha TE; HPTN 024 Study Team. Histologic Chorioamnionitis, Antibiotics and Adverse Infant Outcomes in a Predominantly HIV-1-Infected African Population . Am J Obstet Gynecol. 2006, 195: 1065-74.

Goldenberg RL, Mwatha A, Read JS, Adeniyi-Jones S, Sinkala M, Msmanga G, Martinson F, Hoffman I, Fawzi W, Valentine M, Emel L, Brown E, Mudenda V, Taha TE; HPTN024 Team. The HPTN 024 Study: the efficacy of antibiotics to prevent chorioamnionitis and preterm birth . Am J Obstet Gynecol. 2006, 194: 650-61.

Goulder PJ, Tang Y, Brander C, Betts M, Altfeld M, Annamalai K, Trocha A, He S, Rosenberg E, Ogg G, O’Callaghan CA, Kalams SA, McKinney,Jr. RE, Mayer K, Koup RA, Pelton SI, Burchett SK, McIntosh K, Walker BD. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children . J Exp Med. 2000, 192: 1819-32.

Gregson S, Machekano R, Donnelly CA, Mbizvo MT, Anderson RM, Katzenstein DA. Estimating HIV incidence from age-specific prevalence data: comparison of concurrent cohort estimates in a study of male factory workers, Harare, Zimbabwe . AIDS. 1998, 12: 2049-58.

Gross M, Buchbinder SP, Celum C, Heagerty P, Seage GR, 3rd. Rectal microbicides for U.S. gay men. Are clinical trials needed? Are they feasible? HIVNET Vaccine Preparedness Study Protocol Team. . Sex Transm Dis. 1998, 25: 296-302.

Gross M, Buchbinder SP, Holte S, Celum CL, Koblin BA, Douglas JM, Jr.. Use of reality female condoms for anal sex by US men who have sex with men. HIVNET Vaccine Preparedness Study Protocol Team . Am J Public Health. 1999, 89: 1739-41.

Gross M, Celum CL, Tabet SR, Kelly CW, Coletti AS, Chesney MA. Acceptability of a bioadhesive nonoxynol-9 gel delivered by an applicator as a rectal microbicide . Sex Transm Dis. 1999, 26: 572-578.

Gross M, Holte S, Seage GR 3rd, Buchbinder SP, Metzger DS, Mayer KH. Feasibility of chemoprophylaxis studies in high risk HIV-seronegative populations . AIDS Educ Prev. 2000, 12: 71-8.

Gross M, Holte SE, Marmor M, Mwatha A, Koblin BA, Mayer KH. Anal sex among HIV-seronegative women at high risk of HIV exposure. The HIVNET Vaccine Preparedness Study 2 Protocol Team . J Acquir Immune Defic Syndr. 2000, 24: 393-8.

Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial . Lancet. 1999, 354: 795-802.

Gwanzura L, McFarland W, Alexander, Burke RL, Katzenstein DA. Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe . J Infect Dis. 1998, 177: 481-4.

Halperin DT, Weiss HA, Hayes R, Auvert B, Bailey RC, Caldwell J, Coates T, Padian N, Potts M, Ronald A, Short R, Williams B, Klausner J. Response to Ronald Gray, Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda ( 2000, 14:2371-2381) . AIDS. 2002, 16: 810-2.

Halpern SD, Metzger DS, Berlin JA, Ubel PA. Who will enroll? Predicting participation in a phase II AIDS vaccine trial . J Acquir Immune Defic Syndr. 2001, 27: 281-8.

Hardick A, Hardick J, Wood BJ, Gaydos C. Comparison between the Gen-Probe transcription-mediated amplification Trichomonas vaginalis research assay and real-time PCR for Trichomonas vaginalis detection using Roche LightCycler instrument with self-obtained vaginal swab and male urine samples. . J Clin Microbiol. 2006, 44: 4197-9.

Hardick J, Giles J, Hardick A, Hsieh YH, Quinn T, Gaydos C. Performance of the gen-probe transcription-mediated [corrected] amplification research assay compared to that of a multitarget real-time PCR for Mycoplasma genitalium detection . J Clin Microbiol. 2006, 44: 1236-40.

Harrison LH, do Lago RF, Friedman, RK, Rodrigues L, Santos EM, de Melo MF, Moulton LH, Schechter, M. Incident HIV Infection in a high- risk, homosexual male cohort in Rio de Janeiro, Brazil . J Acquir Immune Defic Syndr. 1999, 21: 408-12.

Hirschhorn L, Kunches L, Mayer K. Nonoccupational Postexposure Prophylaxis. Evolving Clinical Practice . AIDS Clinical Care. 2000, 12: 6-12.

Hofer CB, Harrison LH, Struchiner CJ, Moreira RI, do Lago RF, de Melo MF, Schechter M. Acute retrovirus syndrome among prospectively identified homosexual men with incident HIV infection in Brazil. The Projecto Praca Onze Study Group. Journal of Acquired Immune Deficiency Syndrome . J Acquir Immune Defic Syndr. 2000, 25: 188-91.

Hoffman IF, Taha TE, Padian NS, Kelly CW, Welch JD, Martinson FE, Kumwenda NI, Rosenberg ZF, Chilongozi DA, Brown JM, Chirenje M, Richardson BA. Nonoxynol-9 100 mg gel: multi-site safety study from sub-Saharan Africa . AIDS. 2004, 18: 2191-5.

Huang W, Eshleman SH, Toma J, Fransen S, Stawiski E, Paxinos EE, Whitcomb JM, Young AM, Donnell D, Mmiro F, Musoke P, Guay LA, Jackson JB, Parkin NT, Petropoulos CJ. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations . J Virol. 2007, 81: 7885-93.

Hughes JP, Goldenberg R, Wilfert CM, Valentine M, Mwinga KG. Design of the HIV Prevention Trials Network (HPTN) Protocol 054: A cluster randomized crossover trial to evaluate combined accessto nevirapine in developing countries . UW Biostatistics Working Paper Series. 2004, 195: .

Hughes JP, Richardson BA. Analysis of a randomized trial to prevent vertical transmission of HIV-1 . JASA. 2000, 95: 1032-43.

Hultin LE, Menendez FA, Hultin PM, Jamieson BD, O'Gorman MR, Borowski L, Matud JL, Denny TN, Margolick JB.. Assessing immunophenotyping performance: proficiency-validation for adopting improved flow cytometry methods . Cytometry B Clin Cytom. 2007, 72B: 249-55.

Jackson B, Mmiro F, HIVNET 012 Study Team. HIVNET 012 and Petra (authors' reply) . Lancet. 2004, 363: 244.

Jackson JB, Barnett S, Piwowar-Manning E, Apuzzo L, Raines, C, Hendrix C, Hamzeh F, Gallant J. A Phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk . AIDS. 2003, 17: 547-53.

Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler MG, Mofenson LM, Mirochnick M, Mmiro F, Eshleman SH. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission . AIDS. 2000, 14: F111-5.

Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Owor M, Ducar C, Deseyve M, Mwatha A, Emel L, Duefield C, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Gigliotti M, Bray D, Mmiro F. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial . Lancet. 2003, 362: 859-68.

Jackson JB, Parsons T, Musoke P, Nakabiito C, Donnell D, Fleming T, Mirochnick M, Mofenson L, Fowler MG, Mmiro F, Guay L. Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission . AIDS. 2006, 20: 217-22.

Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, Hecht FM, Jack N, Cleghorn FR, Kahn JO, Chesney MA, Busch MP. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes . JAMA. 1998, 280: 42-48.

Joglekar N, Joshi S, Kakde M, Fang G, Cianciola M, Reynolds S, Mehendale S; HIV Prevention Trial Network 047 Protocol Team. Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India . AIDS Care. 2007, 19: 817-21.

John GC, Sheppard H, Mbori-Ngacha D, Nduati R, Maron D, Reiner M, Kreiss J. Comparison of techniques for HIV-1 RNA detection and quantitation in cervicovaginal secretions . J Acquir Immune Defic Syndr. 2001, 26: 170-5.

Jones D, Parkin N, Hudelson SE, Guay LA, Musoke P, Mmiro F, Jackson JB, Eshleman SH. Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine . AIDS Res Hum Retroviruses. 2005, 21: 319-24.

Joshi S, Dutta S, Bell B, Profy A, Kuruc J, Fang G, Cianciola M, Maslankowski L, Soto-Torres L, Panchanadikar A, Mehendale S, Reynolds SJ. Documenting intermenstrual bleeding in a vaginal microbicide study: case reports and lessons learned . AIDS Res Hum Retroviruses. 2006, 22: 294-6.

Joshi S, Dutta S, Bell B, Profy A, Kuruc J, Gai F, Cianciola M, Soto-Torres L, Panchanadikar A, Risbud A, Mehendale S, Reynolds SJ. Phase I safety study of 0.5% PRO 2000 vaginal Gel among HIV un-infected women in Pune, India . AIDS Res Ther (Epub). 2006, 3: 4.

Kawichai S, Celentano DD, Chariyalertsak S, Visrutaratna S, Short O, Ruangyuttikarn C, Chariyalertsak C, Genberg B, Beyrer C, Konda KA, Celentano D. Community-based voluntary counseling and testing services in rural communities of Chiang Mai Province, Northern Thailand . AIDS Behav. 2007, 11: 770-7.

Keating SM, Bollinger RC, Quinn TC, Jackson JB, Carruth LM. Cross-clade T Lymphocyte Mediated Immunity to HIV-1: Implications for Vaccine Design and Immunodetection Assays . AIDS Res Hum Retroviruses. 2002, 18: 1067-79.

Kilmarx PH, Paxton L, Van Damme L, Rees h, Ramjee G, Laga M, Mâsse B. Need for a true placebo for vaginal microbicide efficacy trials . Lancet. 2003, 361: 785-786.

Klevytska AM, Mracna MR, Guay L, Becker-Pergola G, Furtado M, Zhang, L, Jackson JB, and Eshleman SH. Analysis of length variation in the V1-V2 region of env in non-subtype B HIV-1 from Uganda . AIDS Res Hum Retroviruses. 2002, 18: 791-6.

Koblin B, Chesney M, Coates T; EXPLORE Study Team. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study . Lancet. 2004, 364: 41-50.

Koblin B, Holte S, Lenderking W, Heagerty P. Readiness for HIV vaccine trials: Changes in willingness and knowledge among high-risk populations in the HIV Network for Prevention Trials . J Acquir Immune Defic Syndr. 2000, 24: 451-7.

Koblin BA, Chesney MA, Husnik MJ, Bozeman S, Celum CL, Buchbinder S, Mayer K, McKirnan D, Judson FN, Huang Y, Coates TJ. High-Risk Behaviors Among Men Who Have Sex With Men in 6 US Cities: Baseline Data From the EXPLORE Study . Am J Public Health. 2003, 93: 926-32.

Koblin BA, Heagerty P, Sheon A, Buchbinder S, Celum C, Douglas JM, Gross M, Marmor M, Mayer K, Metzger D, Seage G. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States . AIDS. 1998, 12: 785-93.

Koblin BA, Husnik MJ, Colfax G, Huang Y, Madison M, Mayer K, Barresi PJ, Coates TJ, Chesney MA, Buchbinder S. Risk factors for HIV infection among men who have sex with men . AIDS. 2006, 20: 731-9.

Kozlov AP, Shaboltas AV, Toussova OV, Verevochkin SV, Masse BR, Perdue T, Beauchamp G, Sheldon W, Miller WC, Heimer R, Ryder RW, Hoffman IF. HIV incidence and factors associated with HIV acquisition among injection drug users in St Petersburg, Russia . AIDS. 2006, 20: 901-6.

Krone MR, Wald A, Tabet SR, Paradise M, Corey L, Celum CL. Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors . Clin Infect Dis. 2000, 30: 261-7.

Kumarasamy N. Generic antiretroviral drugs -- will they be the answer to HIV in the developing world? (commentary) . Lancet. 2004, 364: 3-4.

Kumarasamy N, Flanigan TP, Mahajan AP, Carpenter CC, Mayer KH, Solomon S. Monitoring HIV treatment in the developing world . Lancet Infect Dis. 2002, 2: 656-7.

Kumarasamy N, Mahajan AP, Flanigan TP, Hemalatha R, Mayer KH, Carpenter CCJ, Thyagarajan SP, Solomon S. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries . J Acquir Immune Defic Syndr. 2002, 31: 378-83.

Kumarasamy N, Solomon S, Chaguturu SK, Mahajan AP, Flanigan TP, Balakrishnan P, Mayer KH. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India . AIDS. 2003, 17: 2267-9.

Kumarasamy N, Solomon S, Flanigan TP, Hemalatha R, Thyagarajan SP, Mayer KH. Natural history of human immunodeficiency virus disease in southern India . Clin Infect Dis. 2003, 36: 79-85.

Kumarasamy N, Vallabhaneni S, Cecelia AJ, Yepthomi T, Balakrishnan P, Saghayam S, Flanigan TP, Carpenter CC, Solomon S, Mayer KH. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India . J Acquir Immune Defic Syndr. 2006, 41: 53-8.

Kumwenda N, Hoffman I, Chirenje M, Kelly C, Coletti A, Ristow A, et al. HIV incidence among women of reproductive age in Malawi and Zimbabwe . Sex Transm Dis. 2006, 33: 646-51.

Kumwenda NI, Taha TE, Hoover DR, Markakis D, Liomba GN, Chiphangwi JD, Celentano DD. Three Surveys of HIV-1 Prevalence and Risk Factors Among Men Working at a Sugar Estate in Malawi . Sex Transm Dis. 2002, 29: 366-371.

Kumwenda NI, Taha TE, Hoover DR, Markakis D, Liomba GN, Chiphangwi JD, Celentano DD. HIV-1 incidence among male workers at a sugar estate in rural Malawi . J Acquir Immune Defic Syndr. 2001, 27: 202-8.

Lai S, Chen J, Celentano D, Page JB, Lai H, Yang J, Liu W, McCoy CB, Yu XF. Adoption of injection practices in heroin users in Guangxi Province, China . J Psychoactive Drugs. 2000, 32: 285-92.

Lee EJ, Kantor R, Zijenah L, Sheldon W, Emel L, Mateta P, Johnston E, Wells J, Shetty AK, Coovadia H, Maldonado Y, Adeniyi Jones S, Mofenson L, Contag CH, Bassett M, Katzenstein DA. Breast-milk shedding of drug-resistant HIV-1 Subtype C in women exposed to single-dose nevirapine . J Infect Dis. 2005, 192: 1260-4.

Liu W, Chen J, Rodolph M, Beauchamp G, Masse B, Wang S, Li R, Ruan Y, Zhou F, Leung MK, Lai S, Shao Y, Jackson JB. HIV prevalence among injection drug users in rural Guangxi China . Addiction. 2006, 101: 1493-8.

Lo B, Bayer R. Establishing ethical trials for treatment and prevention of AIDS in developing countries . BMJ. 2003, 327: 337-9.

Lole K, Bollinger RC, Paranjape R, Gadkari D, Kulkarni S, Novak N, Ingersoll R, Sheppard H, Rau S. Full-length human immunodeficiency virus type 1 genomes from subtype c-infected seroconverters in India, with evidence of intersubtype recombination . J Virol. 1999, 73: 152-160.

Machekano R, McFarland W, Hudes E, Bassett MT, Mbizvo MT, Katzenstein D. Correlates of HIV test results seeking and utilization of partner counseling services in a corhort of male factory workers in Zimbabwe . AIDS Behav. 2000, 4: 63-70.

Machekano R, McFarland W, Mbizvo MT, Bassett MT, Katzenstein D, Latif AS. Impact of HIV counselling and testing on HIV seroconversion and reported STD incidence among male factory workers in Harare, Zimbabwe . Central Af J Med. 1998, 44: 98-102.

Machekano RN, Bassett MT, Zhou PS, Mbizvo MT, Latif AS, Katzenstein DA. Report of sexually transmitted diseases by HIV infected men during follow up: time to target the infected? . Sex Transm Infect. 2000, 76: 188-92.

MacQueen K, Alleman P. International Perspectives on the Collection, Storage, and Testing of Human Biospecimens in HIV Research . IRB: Ethics and Human Research. 2008, 30: 9-14.

MacQueen KM, Abdool Karim Q, Sugarman J. Ethics guidance for HIV prevention trials . BMJ. 2003, 327: 340.

Macqueen KM, Namey E, Chilongozi DA, Mtweve SP, Mlingo M, Morar N, Reid C, Ristow A, Sahay S, HPTN 035 Standard of Care Assessment Team. Community perspectives on care options for HIV prevention trial participants . AIDS Care. 2007, 19: 554-60.

MacQueen KM, Sugarman J. Back to the Rough Ground: Working in International HIV Prevention Research as Ethical Debates Continue . IRB: Ethics and Human Research. 2003, 2: 11-13.

Mahajan AP, Hogan JW, Snyder B, Kumarasamy N, Mehta K, Solomon S, Carpenter CC, Mayer KH, Flanigan TP. Changes in Total Lymphocyte Count as a Surrogate for Changes in CD4 Count Following Initiation of HAART: Implications for Monitoring in Resource-Limited Settings . J Acquir Immune Defic Syndr. 2004, 36: 567-575.

Makuhunga P. Dilemmas in motivating project staff and observing ethical considerations in recruitment and retention in Zimbabwe . Research Practitioner. 2006, 7: 214-15.

Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, Koblin B, Seage G. Homozygous and Heterozygous CCR5-32 Genotypes are Associated with Resistence to HIV infection . J Acquir Immune Defic Syndr. 2001, 27: 472-81.

Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG, Jackson JB. The cost effectiveness of a single-dose nevirapine regimen to mother and infant to reduce vertical HIV-1 transmission in sub-Saharan Africa . Ann N Y Acad Sci. 2000, 918: 53-6.

Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG, Jackson JB. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa . Lancet. 1999, 354: 803-9.

Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, Karim SA, Sheppard HW, Gray CM; HIVNET 028 Study Team. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load . J Virol. 2004, 78: 3233-43.

Masemola AM, Mashishi TN, Khoury G, Bredell H, Paximadis M, Mathebula T, Barkhan D, Puren A, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G, McIntyre J, Karim SA, Sheppard HW, Gray CM; HIVNET 028 Study Team.. Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa . J Immunol. 2004, 173: 4607-17.

Mauck C, Rosenberg Z, Van Damme L. Recommendations for the clinical development of topical microbicides: an update . AIDS. 2001, 15: 857-68.

Mayer K, Karim S, Kelly C, Maslankowski L, Rees H, Profy A, Day J, Welch J, Rosenberg Z. Safety and tolerability of vaginal PRO2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women . AIDS. 2003, 17: 321-9.

Mayer K, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S, Bentley M, Chesney M, Rosenberg Z. Safety and tolerability of Buffergel, a novel vaginal microbicide, in women in the United States . Clin Infect Dis. 2001, 32: 476-82.

Mayer K, Vittinghoff E, Bozeman S, Husnik M, Colfax G. Substance use and sexual risk: A participant-and episode-level analysis among a cohort of men who have sex with men . Am J Epidemiol. 2004, 159: 1002-1012.

Mayer KH, Kwong J, Singall R, Boswell S. Non-occupational post-exposure prophylaxis: Clinical issues and public health questions . Medicine and Health/Rhode Island. 2000, 83: 210-3.

Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Masse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L; HPTN 050 Protocol Team. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women . AIDS. 2006, 20: 543-51.

Mayer KH, Rosenberg AE. A 49-Year-Old Man with the Acquired Immunodeficiency Syndrome and a Tibial Lesion, Case Records of the Massachusetts General Hospital . N Eng J Med. 2000, 343: 281-7.

McConnell MS, Stringer JS, Kourtis AP, Weidle PJ, and Eshleman SH. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? . Am J Obstet Gynecol. 2007, 197: S56-S63.

McFarland W, Gwanzura L, Bassett MT, Machekano R, Latif AS, Le C, Parsonnet J, Burke RL, Katzenstein D. Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers . J Infect Dis. 1998, 180: 1459-65.

McFarland W, Mvere D, Shamu R, Katzenstein D. Risk factors for HIV infection among first-time blood donors in Zimbabwe . Transfusion. 1998, 38: 279-84.

Mehendale SM, Shepherd ME, Brookmeyer RS, Semba RD, Divekar AD, Gangakhedkar RR, Joshi S, Risbud AR, Paranjape RS, Gadkari DA, Bollinger RC. Low carotenoid concentration and the risk of HIV seroconversion in Pune, India . J Acquir Immune Defic Syndr. 2001, 26: 352-9.

Mehta S, Manji KP, Young AM, Brown ER, Chasela C, Taha TE, Read JS, Goldenberg RL, Fawzi WW. Nutritional indicators of adverse pregnancy outcomes and mother-to-child transmission of HIV among HIV-infected women . Am J Clin Nutr. 2008, 87: 1639-49.

Messiah A, Navaline H, Davis-Vogel A, Tobin-Fiore D, Metzger D. Sociodemographic and behavioral characteristics associated with timeliness and retention in a six-month follow-up study of high-risk injection drug users . Am J Epidemiol. 2003, 157: 930-9.

Metzger DS, Koblin B, Turner C, Navaline H, Valenti F, Holte S, Gross M, Sheon A, Miller H, Cooley P, Seage GR 3rd. Randomized controlled trial of audio computer-assisted self- interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team . Am J Epidemiol. 2000, 152: 99-106.

Mimiaga MJ, Safren SA, Benet DJ, Manseau MW, DeSousa N, Mayer KH. MSM in HIV-prevention trials are sexual partners with each other: An ancillary study to the EXPLORE intervention . AIDS Behav. 2006, 10: 27-34.

Miotti, PG, Taha, TE, Kumwenda, NI, Broadhead, R, Mtimavalye, LAR, Hoeven, LVD, Chiphangwi, JD, Liomba, G, Biggar, RJ. HIV transmission from breastfeeding: a study from Malawi . JAMA. 1999, 282: 744-9.

Mitchla Z, Sharland M. Current treatment options to prevent perinatal transmission of HIV . Expert Opin Pharmacother. 2000, 1: 239-48.

Moon MW, Khumalo-Sakutukwa GN, Heiman JE, Mbizvo MT, Padian NS. Vaginal microbicides for HIV/STI prevention in Zimbabwe: what key informants say . J Transcult Nurs. 2002, 13: 19-23.

Morin SF, Khumalo-Sakutukwa G, Charlebois ED, Routh J, Fritz K, Lane T, Vaki T, Fiamma A, Coates TJ. Removing barriers to knowing HIV status: same-day mobile HIV testing in Zimbabwe . JAIDS. 2006, 41: 218-24.

Morin SF, Maiorana A, Koester KA, Sheon NM, Richards A. Community Consultation in HIV Prevention Research: A Study of Community Advisory Boards at 6 Research Sites . J Acquir Immune Defic Syndr. 2003, 33: 513-20.

Morris SR, Klausner JD, Buchbinder SP, Wheeler SL, Koblin B, Coates T, Chesney M, Colfax GN. Prevalence and incidence of pharyngeal gonorrhea in a longitudinal sample of men who have sex with men: the EXPLORE study . Clin Infect Dis. 2006, 43: 1284-9.

Morrow K, Rosen R, Richter L, Emans A, Forbes A, Day J, Morar N, Maslankowski L, Profy AT, Kelly C, Abdool Karim SS, Mayer KH. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial . J Womens Health. 2003, 12: 655-66.

Mracna M, Becker-Pergola G, Dileanis J, Guay LA, Cunningham S, Jackson JB, and Eshleman SH. Performance of the Applied Biosystems ViroSeq HIV-1 Genotyping System for Sequence-Based Analysis of Non-Subtype B HIV-1 from Uganda . J Clin Microbiol. 2001, 39: 4323-7.

Mugerwa R, Kaleebu P, Mugyenyi P, Katongole-Mbidde E, Hom D, George K, Kebba A, Johnson JL, Schmidt C, Sempala SD, Kityo C, Byaruhanga R, Mugisha E, Flores J, Sheppard CH, Cao H, Othieno C, Allen M, Salata RA, Ellner J for the HIVNET 007 Protocol Team.. First trial of the HIV-1 vaccine in Africa: Ugandan experience . BMJ. 2002, 324: 226-9.

Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW, Murarka A, Allen M, Fowler MG, Mofenson L, Hom D, Mmiro F, Jackson JB. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006) . AIDS. 1999, 13: 479-86.

National Institutes of Health. Interventions to prevent HIV risk behaviors. National Institutes of Health Consensus Development Conference Statement February 11-13, 1997 . AIDS. 2000, 14 Suppl 2: S85-96.

Ndovi TT, Cao YJ, Fuchs E, Fletcher CV, Guidos A, Hendrix CW. Food affects Zidovudine concentration independent of effects on gastrointestinal absorption . J Clin Pharmacol. 2007, 47: 1366-73.

Ndovi TT, Choi L, Caffo B, Parsons T, Baker S, Zhao M, Rohde C, Hendrix CW. Quantitative assessment of seminal vesicle and prostate drug concentrations by use of a noninvasive method . Clin Pharmacol Ther. 2006, 80: 146-58.

Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, Mugyenyi P, Quinn TC, Bangsberg DR. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda . AIDS. 2007, 21: 965-71.

Padian NS. Evidence-based prevention: increasing the efficiency of HIV intervention trials . J Infect Dis. 2004, 190: 663-5.

Paranjape RS, Gadkari DA, Lubaki M, Quinn TC, Bollinger RC. Cross-reactive HIV-1 Specific CTL in Recent Seroconverters from Pune, India . IJMR. 1998, 108: 35-41.

Pauk J, Huang M, Brodie SJ, Wald A, Koelle DM, Schacker T, Celum C, Selke S, Corey L. Mucosal shedding of human herpesvirus 8 in men . N Engl J Med. 2000, 343: 1369-78.

Pechansky F, von Diemen L, Kessler F, Hirakata V, Metzger D, Woody GE. Preliminary estimates of human immunodeficiency virus prevalence and incidence among cocaine abusers of Porto Alegre, Brazil . J Urban Health. 2003, 80: 115-25.

Pequegnat W, Fishbein M, Celentano D, Ehrhardt A, Garnett G, Holtgrave D, Jaccard J, Schachter J, Zenilman J. NIMH/APPC workgroup on behavioral and biological outcomes in HIV/STD prevention studies: a position statement . Sex Transm Dis. 2000, 27: 127-32.

Potter D, Goldenberg RL, Read JS, Wang J, Hoffman IF, Saathoff E, Kafulafula G, Aboud S, Martinson FE, Dahab M, Vermund SH.. Correlates of syphilis seroreactivity among pregnant women: the HIVNET 024 Trial in Malawi, Tanzania, and Zambia . Sex Transm Dis. 2006, 33: 604-9.

Pruenglampoo B, Ruangyuttikarn C. Thai clinical research coordinator's journey in HIV/AIDS research . Research Practitioner. 2006, 7: 217-18.

Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B; the HPTN 055 Study Team. The Value of Site Preparedness Studies for Future Implementation of Phase 2/IIb/III HIV Prevention Trials: Experience From the HPTN 055 Study . JAIDS. 2008, 47: 93-100.

Ray S, Latif A, Machekano R, Katzenstein DA. Sexual behavior and risk assessment among urban male factory workers in Zimbabwe . Soc Sci Med. 1998, 47: 1431-43.

Richardson BA. Editorial: Nonoxynol-9 as a vaginal microbicide for prevention of sexually transmitted infections: It’s time to move on . JAMA. 2002, 287: 1171-1172.

Richardson BA, Hughes JP. Product limit estimation for infectious disease data when the test for the outcome is measured with uncertainty . Biostatistics. 2000, 1: 341-54.

Richardson BA, Lavreys L, Martin HL Jr, Stevens CE, Ngugi E, Mandaliya K, Bwayo J, Ndinya-Achola J, Kreiss JK. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial . Sex Transm Dis. 2001, 28: 394-400.

Risbud A, Chan-Tack K, Gadkari D, Gangakhedkar R, Shepherd ME, Bollinger RC, Mehendale S, Divekar A, Rompalo A, Quinn TC. The Etiology of genital ulcer disease by multiplex polymerase chain reaction and relationship to HIV infection among patients attending sexuallly transmitted disease clinics in Pune, India . Sex Transm Dis. 1999, 26: 55-62.

Rizzo-Price P, Stamper PD, Wood BJ, Reynolds SJ, Quinn TC, Gaydos C. Can nucleic acid amplification tests be used to test for chlamydia and gonorrhoea in microbicide trials? . Int J STD AIDS. 2007, 18: 543-5.

Rizzo-Price, PA, Stamper P, Wood BW, Reynolds SJ, Quinn TC, Gaydos CA. Can nucleic acid amplification tests be used to test for Chlamydia and Gonorrhea in microbicide trials? . Internat J STD AIDS. 2007, 18: 543-45.

Roesel DJ, Gwanzura L, Mason PR, Joffe M, Katzenstein DA. Polymerase chain reaction of Haemophilus ducreyi DNA . Sex Transm Infect. 1998, 74: 63-5.

Rompalo A, Shah N, Gaydos C, Tennant MK, Crotchfelt K, Madico G, Quinn TC, Daniel R, Shah KT, Gaydos JC, McKee KT, Jr. Evaluation of a single intravaginal swab to detect multiple sexually transmitted infections in active duty women soldiers . Clin Infect Dis. 2001, 33: 1455-61.

Safren SA, Kumarasamy N, Hosseinipour M, Harwood MM ,Hoffman I, McCauley M, Jumbe A, Nyirenda C, Mimiaga MJ, Solomon S, Celentano D, Mayer KH. Perceptions about the acceptability of assessments of HIV medication adherence in Lilongwe, Malawi and Chennai, India . AIDS Behav. 2006, 10: 443-50.

Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S, Mayer K, Wanke C. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India. . Clin Infect Dis. 2007, 44: 295-300.

Sahasrabuddhe VV, Vermund SH. The Future of HIV Prevention: Control of Sexually Transmitted Infections and Circumcision Interventions . Infect Dis Clin North Am. 2007, 21: 241-57.

Schechter M, do Lago RF, de Melo MF, Sheppard HW, Guimaraes NC, Moreira RI, Faulhaber JC, Batista S, Harrison LH. Identification of a high-risk heterosexual population for HIV prevention trials in Rio de Janeiro, Brazil. Projeto Praca Onze Study Group. . Acquir Immune Defic Syndr. 2000, 24: 175-7.

Seage GR 3rd, Holte SE, Metzger D, Koblin BA, Gross M, Celum C, Marmor M, Woody G, Mayer KH, Stevens C, Judson FN, McKirnan D, Sheon A, Self S, Buchbinder SP. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study . Am J Epidemiol. 2001, 153: 619-27.

Shaboltas AV, Toussova OV, Hoffman IF, Heimer R, Verevochkin SV, Ryder RW, Khoshnood K, Perdue T, Masse BR, Kozlov AP. HIV prevalence, sociodemographic, and behavioral correlates and recruitment methods among injection drug users in St. Petersburg, Russia . JAIDS. 2006, 41: 657-63.

Shafer RW, Chaung T, Hsu P, White CB, Katzenstein DA. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe . AIDS Res Hum Retroviruses. 1999, 15: 65-9.

Sheppard HW, Celum CL, Michael NL, O'Brien S, Dean M, Carrington M, Dondero D, Buchbinder SP. HIV-1 infection in individuals with the CCR5-delta32/delta32 genotype: acquisition of syncytium-inducing virus at seroconversion . J Acquir Immune Defic Syndr. 2002, 29: 307-13.

Shetty AK, Coovadia HM, Mirochnick MM, Maldonado Y, Mofenson LM, Eshleman SH, Fleming T, Emel L, George K, Katzenstein DA, Wells J, Maponga CC, Mwatha A, Jones SA, Abdool Karim SS, Bassett MT. Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants From Birth to 6 Months . J Acquir Immune Defic Syndr. 2003, 34: 482-90.

Silverthorn CF, Parsons TL. A validated new method for nevirapine quantitation in human plasma via high-performance liquid chromatography . Biomed Chromatogr. 2006, 20: 23-7.

Sinkala M, Stout JP, Vermund SH, Goldenberg RL, Stringer JSA. Zambian women's attitudes toward mass nevirapine therapy to prevent perinatal transmission of HIV . Lancet. 2001, 358: 1611-12.

Solomon S, Buck J, Chaguturu SK, Ganesh AK, Kumarasamy N. Stopping HIV before it begins: issues faced by women in India . Nat Immunol. 2003, 4: 719-21.

Solomon SS, Solomon S, Masse BR, Srikrishnan AK, Beauchamp G, Thamburaj E, Gulvady M, Anand S, Mayer KH. Risk reduction counseling is associated with decreased HIV transmission-associated behaviors in high-risk Indian heterosexuals . J Acquir Immune Defic Syndr. 2006, 42: 478-83.

Spielberg F, Critchlow C, Vittinghoff E, Coletti AS, Sheppard H, Mayer KH, Metzgerg D, Judson FN, Buchbinder S, Chesney M, Gross M. Home collection for frequent HIV testing: acceptability of oral fluids, dried blood spots and telephone results. HIV Early Detection Study Group . AIDS. 2000, 14: 1819-28.

Spielberg F, Critchlow C, Vittinghoff E, Gross M, Doherty-Iddings P, Scotti R, Judson FN, Marmor M, Buchbinder S. Slow diffusion of home HIV-specimen collection: provider concerns at odds with client preferences . Sex Transm Dis. 2001, 28: 51-7.

Sri Krishnan AK, Hendriksen E, Vallabhaneni S, Johnson SL, Raminani S, Kumarasamy N, Hobsen J, Solomon S, Mayer KH, Safren SA. Sexual behaviors of individuals with HIV living in South India: a qualitative study . AIDS Educ Prev. 2007, 19: 334-45.

Stephenson J. Health agencies update: HIV Prevention Trials Network . JAMA. 2000, 284: 822.

Stone E, Heagerty P, Vittinghoff E, Douglas JM, Jr., Koblin BA, Mayer KH, Celum CL, Gross M, Woody GE, Marmor M, Seage GR, 3rd, Buchbinder SP. Correlates of condom failure in a sexually active cohort of men who have sex with men . J Acquir Immune Defic Syndr Hum Retrovirol. 1999, 20: 495-501.

Stringer EM, Sinkala M, Kumwenda R, Chapman V, Mwale A, Vermund SH, Goldenberg RL, Stringer JS. Personal risk perception, HIV knowledge and risk avoidance behavior, and their relationships to actual HIV serostatus in an urban African obstetric population . J Acquir Immune Defic Syndr. 2004, 35: 60-6.

Stringer JS, Rouse DJ, Vermund SH, Goldenberg RL, Sinkala M, Stinnett AA. Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa . J Acquir Immune Defic Syndr. 2000, 24: 369-77.

Stringer JS, Sinkala M, Chapman V, Acosta EP, Aldrovandi GM, Mudenda V, Stout JP, Goldenberg RL, Kumwenda R, Vermund SH. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine . AIDS. 2003, 17: 1659-65.

Stringer JS, Sinkala M, Goldenberg R, Vermund S, Acosta E. Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1 . Lancet. 2003, 362: 667.

Stringer JS, Sinkala M, Goldenberg RL, Kumwenda R, Acosta EP, Aldrovandi GM, Stout JP, Vermund SH. Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings . AIDS. 2004, 18: 939-43.

Stringer JS, Sinkala M, Rouse DJ, Goldenberg RL, Vermund SH. Effect of nevirapine toxicity on choice of perinatal HIV prevention strategies . Am J Public Health. 2002, 92: 365-6.

Sucato G, Celum CL, Dithmer D, Ashley RL, Wald A. Demographic rather than behavioral risk factors predict herpes simplex virus type 2 infection in sexually active adolescehts . Pediatr Infect Dis. 2001, 20: 422-6.

Summerton J, Riedesel M, Laeyendecker O, Gaydos C, Maldeis NE, Hardick A, Morrow RA, Quinn TC. Effect of sexually transmitted disease (STD) coinfections on performance of three commercially available immunosorbent assays used for detection of herpes simplex virus type 2-specific antibody in men attending Baltimore, Maryland, STD clinics . Clin Vaccine Immunol. 2007, 14: 1545-9.

Tabet S, Sanchez J, Lama J, Goicochea P, Campos P, Rouillon M, Cairo JL, Ueda L, Watts D, Celum C, Holmes K. HIV, syphilis and heterosexual bridging among Peruvian men who have sex with men . AIDS. 2002, 16: 1271-1277.

Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, Moench TR, Soto-Torres LE, Poindexter AN, Frezieres RG, Walsh TL, Kelly CW, Richardson BA, van Damme L, Celum CL. Safety and Acceptability of Penile Application of 2 Candidate Topical Microbicides: BufferGel and PRO 2000 Gel: 3 Randomized Trials in Healthy Low-Risk Men and HIV-Positive Men . J Acquir Immune Defic Syndr. 2003, 33: 476-83.

Tabet SR, Surawicz C, Horton S, Paradise M, Coletti AS, Gross M, Fleming TR, Buchbinder S, Haggitt RC, Levine H, Kelly CW, Celum CL. Safety and toxicity of nonoxynol-9 gel as a rectal microbicide . Sex Transm Dis. 1999, 26: 564-71.

Taha TE, Brown ER, Hoffman IF, Fawzi W, Read JS, Sinkala M, Martinson FE, Kafulafula G, Msamanga G, Emel L, Adeniyi-Jones S, Goldenberg R. A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission . AIDS. 2006, 20: 1313-21.

Taha TE, Dallabetta GA, Hoover DR, Chiphangwi JD, Mtimavalye LA, Liomba GN, Kumwenda NI, Miotti PG. Trends of HIV-1 and sexually transmitted diseases among pregnant and postpartum women in urban Malawi . AIDS. 1998, 12: 197-203.

Taha TE, Graham SM, Kumwenda NI, Broadhead RL, Hoover DR, Markakis D, van Der Hoeven L, Liomba GN, Chiphangwi JD, Miotti PG. Morbidity among human immunodeficiency virus-1-infected and -uninfected African children . Pediatrics. 2000, 106: E77.

Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LA, Yang LP, Liomba GN, Broadhead RL, Chiphangwi JD, Miotti PG. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV . AIDS. 1998, 12: 1699-706.

Taha TE, Hoover DR, Kumwenda NI, Fiscus SA, Kafulafula G, Nkhoma C, Chen S, Piwowar E, Broadhead RL, Jackson JB, Miotti PG. Late postnatal transmission of HIV-1 and associated factors . J Infect Dis. 2007, 196: 10-14.

Taha TE, Kumwenda NI, Hoover DR, Biggar RJ, Broadhead RL, Cassol S, van der Hoven L, Markakis D, Liomba GN, Chiphangwi JD, Miotti PG. Association of HIV-1 load and CD4 lymphocyte count with mortality among untreated African children over one year of age . AIDS. 2000, 14: 453-9.

Taha TE, Kumwenda NI, Hoover DR, Fiscus SA, Kafulafula G, Nkhoma C, Nour S, Chen S, Liomba G, Miotti PG, Broadhead RL. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting; a randomized controlled trial . JAMA. 2004, 292: 202-9.

Taha TE, Kumwenda, NI, Broadhead, RL, Hoover, DR, Graham, SM, Hoeven, LV,D, Markakis, D, Liomba, GN, Chiphangwi, JD, Miotti, PG. Mortality after the first year of life among HIV infected and uninfected children . Ped Infect Dis J. 1999, 18: 689-94.

TahaTE, Kumwenda N, Gibbons A, Hoover D, Lema V, Fiscus S, Mukiibi J, Liomba G, Broadhead R. Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants . AIDS. 2002, 16: 851-8.

Tien PC, Chiu T, Latif AS, Ray S, Batra M, Contag CH, Zejenah L, Mbizvo M, Delwart EL, Mullins JI, Katzenstein DA. Primary subtype C HIV-1 infection in Harare, Zimbabwe . J Acquir Immune Defic Syndr Hum Retrovirol. 1999, 20: 147-53.

Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B . Clin Microbiol Rev. 2007, 20: 426-39.

van De Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, Kumwenda N, Chirenje Z, Joshi S, Taha T, Padian N, Bollinger R, Nelson K. Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites . J Acquir Immune Defic Syndr. 2001, 26: 21-7.

Vermund SH. Vaccine efficacy trials for human immunodeficiency virus/acquired immunodeficiency syndrome are feasible in the United States: a commentary on the HIVNET Vaccine Preparedness Study . Am J Epidemiol. 2001, 153: 630-1.

Wei L, Chen J, Rodolph M, Beauchamp G, M 0226 Sse B, Li R, Wang S, Ruan Y, Lai S, Zhang L, Zhou F, Rose SM, Perdue T, Lai S, Shao Y, Jackson JB.